< Back to companies
IASO BioTherapeutics (驯鹿医疗)

IASO BioTherapeutics (驯鹿医疗)

Nanjing, China

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates.

Only accessible to MedStartr community members. Join now

Company Info

Founded
2017
Website
www.iasobio.com/

Categories

Drug DevelopmentCancer CareBiotechTherapeutics
Only accessible to MedStartr community members. Join now

What do you think of IASO BioTherapeutics (驯鹿医疗)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now